The cardiovascular and soft tissue repair patches market valued around $ 2,499 million in 2014and is estimated at $ 5,792 million over the forecast period. The major trigger of the market growth are raising occurrence of congenital heart diseases like common atrium, ventricular septal defect, and atrial septal defect. These patches are used for procedures of tissue repair like dural repair, vascular repair and reconstructions, and soft tissue repairs.
For Market Research Report on “Cardiovascular and soft tissue repair patches market” Visit -http://www.grandviewresearch.com/industry-analysis/cardiovascular-soft-tissue-repair-patches-market
In addition, growing occurrence of hernia, for example, congenital diaphragmatic hernia, inguinal hernia, and other are anticipated to considerably enhance the rate of usage over the forecast period. The basic fast growing feature is raising association amongst different organizations doing research, manufacturers, and suppliers of raw materials. Additional features like expansion of fresh technologies via biological materials, tissue manufacturing materials, are also anticipated to drive the market of the devices.
The cardiovascular and soft tissue patches market is highly split due to various raw materials, varied prices, and various product sizes used. Specific sizes are needed for each purpose and hence these are accessible in sizes from 0.8 X 0.8 cm, 1 x1 cm, 2 x 9 cm to 10 x 15 cm. The market is divided into applications, raw materials, and regions.
The market on the basis of applications is divided into soft tissue repair, cardiac repair, dural & pericardial repair, and vascular repair and reconstruction. The soft tissue repair had majority share of more than 30% in 2014 due to growing occurrence of different hernias.
In addition, the cardiac repair sector is estimated the fastest increasing application of cardiovascular and soft tissue repair patches market rising at 11.5% CAGR. The most common heart diseases amongst paediatric populace is congenital, which is anticipated to steer the requirement for cardiac patches over the forecast period.
The major raw-material used in cardiovascular and soft tissue patches is biomaterial, ePTFE, and tissue engineered material. Biomaterial and ePTFE are the two major raw materials for manufacture usage. Additionally, ePTFE had the maximum share of more than 66% in 2014.
Asia Pacific had the major share in 2014 due to hernias and congenital heart diseases. North America is anticipated to grow the fastest over the period. The major companies are Cryolife, Bard Peripheral Vascular Inc, Edwards Life Sciences, and Baxter which generate maximum revenue.
Information Source: Grand View Research